474 filings
Page 5 of 24
4
jz3wcx7lgomdkb m2rl
10 Jan 23
ANAPTYSBIO / ERIC J LOUMEAU ownership change
7:08pm
4
um9 ljxslr28z0ee669p
10 Jan 23
ANAPTYSBIO / Paul F. Lizzul ownership change
7:07pm
4
z8bk1xq a53ut5
10 Jan 23
ANAPTYSBIO / Laura Hamill ownership change
7:07pm
4
ojn3 swsevgh0bx47bnh
10 Jan 23
ANAPTYSBIO / DENNIS M FENTON ownership change
7:06pm
4
9uhpljlnlu ctwa1
10 Jan 23
ANAPTYSBIO / Daniel Faga ownership change
7:04pm
8-K
4ikn 7fjjka
5 Jan 23
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
4:12pm
424B5
lp1rye6
8 Nov 22
Prospectus supplement for primary offering
4:34pm
8-K
zlzzc0nfb3b3h
8 Nov 22
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
4:08pm
4
416szvuh
16 Sep 22
ANAPTYSBIO / Paul F. Lizzul ownership change
5:08pm
4
yae38i1g26n0867twmg
16 Sep 22
ANAPTYSBIO / ERIC J LOUMEAU ownership change
5:07pm
4
o8eg k9noiv0
16 Sep 22
ANAPTYSBIO / DENNIS MULROY ownership change
5:06pm
8-K
628l0uak
12 Sep 22
Entry into a Material Definitive Agreement
7:32am
SC 13G
manxrgx0l jk6
9 Sep 22
ANAPTYSBIO / Point72 Asset Management ownership change
4:54pm
8-K
ko2vthmddmyj0tzm
31 Aug 22
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
4:19pm
SC 13G
hte7 n1f0
15 Aug 22
ANAPTYSBIO / Flynn James E ownership change
5:47pm
4
dd35a4ukz
9 Aug 22
ANAPTYSBIO / ERIC J LOUMEAU ownership change
12:00am
8-K
lpeiwkt
8 Aug 22
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
4:21pm
4
mjdub
27 Jun 22
ANAPTYSBIO / DENNIS MULROY ownership change
7:06pm